EPISODE · Feb 3, 2026 · 17 MIN
Merck & Co. Q4 2025 Earnings and Strategic Outlook
from Daily Market Download · host Daily Market Download
Merck’s Q4 2025 results highlight the strategic acquisition of Cidara Therapeutics and the clinical success of Winrevair in PAH. Despite a Gardasil sales decline in Asia and generic headwinds, the firm projects a $70 billion pipeline opportunity driven by oncology and HIV gains.
What this episode covers
Merck’s Q4 2025 results highlight the strategic acquisition of Cidara Therapeutics and the clinical success of Winrevair in PAH. Despite a Gardasil sales decline in Asia and generic headwinds, the firm projects a $70 billion pipeline opportunity driven by oncology and HIV gains.
NOW PLAYING
Merck & Co. Q4 2025 Earnings and Strategic Outlook
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m